Sjogren's Syndrome

被引:1
作者
Corominas, Hector [1 ]
Figuls, Ramon [1 ]
Riera, Manel [1 ]
机构
[1] Hosp Dos Maig, Unitat Reumatol, Maig,301, E-08025 Barcelona, Spain
来源
REUMATOLOGIA CLINICA | 2008年 / 4卷
关键词
Sjogren's syndrome; Keratoconjunctivitis sicca; Xerostomy;
D O I
10.1016/S1699-258X(08)76135-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sjogren's syndrome is a systemic autoimmune disease that is characterized by the presence of keratoconjunctivitis sicca, xerostomy and a large spectrum of signs and symptoms that translate into a very heterogeneous disease. The mild form that affects mucosal tissues is the most frequent, but there are more severe and active patterns, manifested by the presence of extraglandular affection with a worse prognosis. The clinical spectrum includes anything from mucosal alterations, Raynaud's phenomenon, parotid enlargement or arthritis, but can be aggravated by the presence of neurological, lung or renal affection. Initial therapy includes topical treatment with artificial tears, nocturnal cream and drugs that stimulate secretion for important glandular affection, while severe systemic affection merits immunosuppressant therapy. There has been recent evidence that biologic therapy is useful for the treatment of severe and resistant cases.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 36 条
[1]   Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab [J].
Ahmadi-Simab, K ;
Lamprecht, P ;
Nölle, B ;
Ai, M ;
Gross, WL .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :1087-1088
[2]   Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003 [J].
Alamanos, Y ;
Tsifetaki, N ;
Voulgari, PV ;
Venetsanopoulou, AI ;
Siozos, C ;
Drosos, AA .
RHEUMATOLOGY, 2006, 45 (02) :187-191
[3]   Dental and periodontal status of Sjogren's syndrome [J].
Boutsi, EA ;
Paikos, S ;
Dafni, UG ;
Moutsopoulos, HM ;
Skopouli, FN .
JOURNAL OF CLINICAL PERIODONTOLOGY, 2000, 27 (04) :231-235
[4]   Predicting adverse outcomes in primary Sjogren's syndrome:: identification of prognostic factors [J].
Brito-Zeron, P. ;
Ramos-Casals, M. ;
Bove, A. ;
Sentis, J. ;
Font, J. .
RHEUMATOLOGY, 2007, 46 (08) :1359-1362
[5]   Results of the treatment with oral pilocarpine in 100 patients with primary Sjogren's syndrome [J].
Brito-Zeron, Pilar ;
Ramos-Casals, Manuel ;
Nardi, Norma ;
Font, Josep .
MEDICINA CLINICA, 2006, 126 (16) :637-637
[6]   Prevalence of Sjogren's syndrome in a closed rural community [J].
Dafni, UG ;
Tzioufas, AG ;
Staikos, P ;
Skopouli, FN ;
Moutsopoulos, HM .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (09) :521-525
[7]   Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20) [J].
Devauchelle-Pensec, Valerie ;
Pennec, Yvon ;
Morvan, Johanne ;
Pers, Jacques-Olivier ;
Daridon, Capucine ;
Jousse-Joulin, Sandrine ;
Roudaut, Anne ;
Jamin, Christophe ;
Renaudineau, Yves ;
Roue, Isabelle Quintin ;
Cochener, Beatrice ;
Youinou, Pierre ;
Saraux, Alain .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (02) :310-317
[8]  
Diaz-Lopez C, 2004, J RHEUMATOL, V31, P1352
[9]   Subgroups of primary Sjogren's syndrome. Sjogren's syndrome in male and paediatric Greek patients [J].
Drosos, AA ;
Tsiakou, EK ;
Tsifetaki, N ;
Politi, EN ;
SiamopoulouMavridou, A .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (05) :333-335
[10]   The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome [J].
Font, J ;
García-Carrasco, M ;
Ramos-Casals, M ;
Aldea, AI ;
Cervera, R ;
Ingelmo, M ;
Vives, J ;
Yagüe, J .
RHEUMATOLOGY, 2002, 41 (09) :1025-1030